Issued 2026-08-13 at $43.56 · now $43.18 (2026-08-13, −0.9% since)
Based on its own history, a month from the 2026-08-13 close, EWTX has typically landed between $32.79 and $61.59 — a range of −24.7% to +41.4% from the issuance price $43.56.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,331 overlapping 1 month windows · 2021-03-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($43.56) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where EWTX has typically landed a month from the 2026-08-13 close of $43.56 — the range is history, not a prediction.
- now $43.18 (-0.9%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $43.69 (+0.3%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $38.78–$48.61
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $32.79–$61.59
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-03-06 | −59.1% | −59.1% | +0.0% |
| 2025-03-10 | −58.3% | −58.3% | +0.0% |
| 2025-03-07 | −57.8% | −58.9% | +0.0% |
| 3 best | |||
| 2024-01-11 | +104.9% | +0.0% | +115.9% |
| 2024-09-16 | +95.7% | +0.0% | +95.7% |
| 2023-11-27 | +94.8% | −3.5% | +94.8% |
1,331 overlapping windows · 2021-03-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 2 primary completion: Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) (source, as of 2026-08-14)
- January 2027 — Trial primary completion: Phase 2 primary completion: A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) (source, as of 2026-08-14)
- March 2027 — Trial primary completion: Phase 2 primary completion: Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy (source, as of 2026-08-14)
- December 2027 — Trial primary completion: Phase 2 primary completion: A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) (source, as of 2026-08-14)
- February 2031 — Trial primary completion: Phase 2 primary completion: Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.